Gastrointestinal adverse events with combination of checkpoint inhibitors in advanced melanoma: a systematic review

INTRODUCTION: Immunotherapies, including checkpoint inhibitors (CIs) such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) inhibitors, are revolutionizing the treatment of advanced melanoma. Combining CTLA-4 and PD-1 inhibitors provides additional clinical benefit compared...

Descripción completa

Detalles Bibliográficos
Autores principales: Mearns, Elizabeth S, Bell, Jill A, Galaznik, Aaron, Puglielli, Stefanie M, Cichewicz, Allie B, Boulanger, Talia, Garcia-Ribas, Ignacio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2018
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122526/
https://www.ncbi.nlm.nih.gov/pubmed/30190927
http://dx.doi.org/10.2217/mmt-2017-0027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122526/
https://www.ncbi.nlm.nih.gov/pubmed/30190927
http://dx.doi.org/10.2217/mmt-2017-0027

Ejemplares similares